Excindogen - Vitalgenics
Latest Information Update: 03 Nov 2022
At a glance
- Originator Vitalgenics
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pancreatic cancer
Most Recent Events
- 27 Sep 2022 Phase-I clinical trials in Pancreatic cancer in USA (unspecified route) (Vitalgenics website, September 2022)
- 09 Sep 2021 Excindogen receives Orphan Drug status for Pancreatic cancer
- 09 Sep 2021 Pharmacodynamics and adverse events data from preclinical studies in Pancreatic cancer released by Vitalgenics